论文部分内容阅读
采用微量稀释法测定了5-氨基-1-环丙基-6,8-二氟-1,4-二氢-7-(3-甲基-1-哌嗪基)-4-氧代喹啉-6-羧酸(YH37)对临床分离的人型支原体(Mh)、解脲脲原体(Uu)以及细菌标准菌株的体外敏感性。结果显示,YH37对Mh的抑制活性较强,MIC90为0.25mg/L,是司帕沙星的1/8;对Uu的MIC90为1mg/L,是司帕沙星的1/4。YH37对Mh、Uu的喹诺酮耐药株有一定的抑制活性,其MIC分别为CPLX的1/4～1/16。YH37对被测细菌的抑制活性是左氧氟沙星的1/8～1/16,是司帕沙星的1/2。
5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7- (3-methyl-1-piperazinyl) -4-oxoquine In vitro susceptibility of clinically isolated Mycoplasma hominis (Mh), Uu (Uu), and bacterial standard strains was achieved using a spectrophotometric method for the determination of 5-hydroxybutyrate (YH37). The results showed that YH37 had a strong inhibitory activity on Mh with a MIC90 of 0.25 mg / L, which was 1/8 of that of sparfloxacin. The MIC90 of Uh was 1 mg / L, which was 1/4 of sparfloxacin. YH37 had some inhibitory activities against quinolone-resistant strains of Mh and Uu, with MICs of 1/4 to 1/16 of CPLX, respectively. The inhibitory activity of YH37 against the tested bacteria was 1/8 to 1/16 of levofloxacin and 1/2 of sparfloxacin.